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Youth onset type 2 diabetes (T2DM) continues to increase worldwide, concomitant with the rising obesity epidemic. There is
evidence to suggest that youth with T2DM are aﬀected by the same comorbidities and complications as adults diagnosed with
T2DM. This review highlights speciﬁcally the kidney disease associated with youth onset T2DM, which is highly prevalent and
associated with a high risk of end-stage kidney disease in early adulthood. A general understanding of this complex disease by
primary care providers is critical, so that at-risk individuals are identiﬁed and managed early in the course of their disease,
such that progression can be modiﬁed in this high-risk group of children and adolescents. A review of the pediatric literature
will include a focus on the epidemiology, risk factors, pathology, screening, and treatment of kidney disease in youth onset
T2DM.
1.EpidemiologyofYouthOnset Type2 Diabetes
Type 2 diabetes (T2DM) has been described in children and
adolescents since the 1980s [1], and coincident with the
rising obesity epidemic, the incidence and prevalence have
continued to rise over the last thirty years [2, 3]. Youth onset
T2DM has now been described around the world, including
Canada, Japan, India, Australia, the United States (US), and
theUnitedKingdom(UK)[4–9].Thehighest rateshavebeen
reported in the Pima Indian population in the US, with a
prevalence of 1.4% in boys and 2.88% in girls between 10
and 14 years [10]. In Canadian First Nation children 4–19
years of age, the prevalence has been reported to be as high
as 1% in some communities [11]. In most otherpopulations,
although rates are increasing, the disease remains compara-
bly rare. In the US, for example, the incidence in 10–14 years
old is 8.1/100,000 person years, and 11.8 per 100,000 person
years in children 15–19 years [12]. In Canada, a recent active
surveillance initiative revealed a minimum incidence rate of
T2DM in children less than 18 years of 1.54 per 100,000 per
year. The highest rate was seen in the province of Manitoba,
witha minimumincidencerateof12.45per100,000children
[13]. The lowest rates have been reported in the UK at 0.53
per 100,000 in less than 17 year olds [14].
In addition to obesity, multiple other risk factors for the
development of youth onset T2DM have been identiﬁed.
Firstly, most aﬀected children belong to minority ethnic
groups including Canadian First Nation, American Indian,
Hispanic, African-American, and Indo-Asian [6]. T2DM re-
presents only 6% of non-Hispanic white children in the US
with diabetes [15] but accounts for 46.1% of newly diag-
nosed Hispanics, 57.8% of non-Hispanic blacks, 69.7% of
Asian Paciﬁc Islanders, and 86.2% of American Indians with
youth onset diabetes [12].
A strong family history is almost universal, with 45–80%
of children with T2DM having at least one parent and 70–
100% having a ﬁrst or second-degree relative aﬀected with
the disease [16, 17]. The intrauterine environment has also
been shown to be important. Children at the lowest and
highest extremes of birth weight are at increased risk [18],
as are those exposed to pregestational or gestational diabetes
in utero [19, 20]. In contrast, breastfeeding has been shown
to be protective [19, 20]. Finally, speciﬁc genetic factors
may play an important role. For example, a unique hepatic2 International Journal of Pediatrics
nuclear factor- (HNF-)1α is a transcription factor expressed
in many tissues including the liver, intestine, pancreatic β-
cell, and kidney. A polymorphism of this gene (HNF-1α
G319S)hasbeenidentiﬁed intheOji-Cree languagegroupof
First Nation people in Manitoba and northwestern Ontario.
It is associated with an insulin-secretory defect, which
predisposes to early onset T2DM in this population [21, 22].
2.NephropathyAssociatedwithType2Diabetes
In adults, T2DM is the leading cause of end-stage kidney
disease (ESKD) accounting for 30–40% of cases in most
countries. ESKDsecondary todiabeticnephropathytypically
manifests after 20 to 30 years of diabetes exposure [23]. In
children and adolescents, diabetes accounts for only 0.1% of
ESKD [24]. However, there is mounting evidence to suggest
that renal complications in youth onset T2DM manifest
themselvesearlyinthecourseofdisease,andthatprogression
parallels that seen in adult onset T2DM [25]. As youth onset
T2DM has only been described for twenty years, we are just
now starting to see the impact of the renal complications
associated with this devastating disease, as the ﬁrst cohort of
youth enter their third decade.
Microalbuminuria is the ﬁrst manifestation of a renal
complicationofdiabetes and isthemost commonly reported
complication of T2DM in youth [26–30]. Reported rates
vary widely between 7 and 22% at presentation [27, 28, 31]
and between 9.6 and 72% within 3–10 years after diagnosis
[26–32]. Variation in rates depends mainly on the deﬁnition
of albuminuria utilized in each study. Most studies report
albuminuria in one random urine sample, which overesti-
mates the prevalence of pathologic albuminuria, as urinary
albumin excretion can be transient. Studiesthathaveutilized
more stringent criteria (2 out of 3 abnormal samples over
a 3–6 month period) report more conservative rates, such
as the TODAY study cohort, which reported a prevalence of
albuminuria of 13% at a mean age of 14 years, and mean
diabetes duration of 7.8 months [33]. This cohort had an
averagehemoglobinA1c(HbA1c)of5.9% at enrollment and
is therefore likely a low-risk group. In contrast, rates of
microalbuminuria in a Manitoba, Canada, cohort with an
average HbA1c of 8.9%, based on at least 2 abnormal sam-
ples, are much higher at 26.9%, at a mean age of 16.5 years
and mean duration of diabetes of 3 years [34]. There has yet
to be a study in youth that has reported rates of persistent
albuminuria conﬁrmed with a ﬁrst morning urine sample
or overnight urine collection, which are considered the gold
standard tests. Nevertheless, these high rates in adolescence
are concerning, as microalbuminuria is predictive of pro-
gressivediabeticnephropathy,decliningglomerularﬁltration
rate (GFR), and cardiovascular disease [35–38].
In the Pima Indian populationofthe US,there is a 5-fold
increased risk of age-speciﬁc ESKD in those diagnosed with
diabetesbeforethe ageof20compared tothose with diabetes
onset between 25 and 54 years of age [39]. However, after
controlling for confounders, age at onset was no longer asso-
ciated with an increased incidence of ESKD, suggesting that
the longer duration of diabetes accounted for the increased
risk in middle age. These results are in keeping with a pre-
vious study by Krakoﬀ et al. which directly compared youth
with T2DM <20 years at diagnosis versus young adults 20–
39 years versus older adults >40 years at diagnosis which did
not show a diﬀerence in risk of nephropathy over 25 years
between groups [25]. What remains especially concerning,
however, is the young age at which youth with T2DM will
reachESKD,requiringdialysisorkidneytransplanttosustain
life. In Manitoba, ESKD has previously been reported to
occur prior to the age of 30 years in young adults diagnosed
with T2DM prior 18 years [40]. The same cohort has also
recently been shown to have a 4-fold increased risk of
ESKD compared to youth with type 1 diabetes (T1DM). In
addition, the renal survival ﬁfteen years after diagnosis is
92%, and only 55% in those individuals with 20 years of
followup [34]. A higher incidence of nephropathy in young
adults with T2DM compared to those with T1DM has also
beenreportedintheJapanesepopulation[41].Asubgroupof
this population with proliferative retinopathy prior to age 35
was associated with diabetic nephropathy in 60% and renal
failure in 23%, with a requirement for renal replacement
therapy at 35 years of age [42].
3.RiskFactorsforProgression
Kim et al. followed youth with T2DM longitudinally for a
median of 3 years, and microalbuminuria identiﬁed on one
initial urine assessment remained persistent in >93% of
youth less than 20 years of age [45]. This study also demon-
strated thatmicroalbuminuriainadolescentswithT2DMisa
predictorofprogression tomacroalbuminuria overa median
followup of 8.1 years [45]. Albuminuria detected in adoles-
cence has also been associated with a 4-fold increased risk of
renal failure in early adulthood [34]. Microalbuminuria can
therefore be considered a harbinger of renal injury in youth
with T2DM, consistent with adult onset T2DM.
The adult literature has identiﬁed clinical risk factors
associated with the development of diabetic nephropathy.
There may also be a genetic predisposition, as has been
s h o w ni nt h eP i m aI n d i a n si nt h eU S[ 46]a sw e l la si nC a u -
casians [47]. A study of 191 normoalbuminuric adults with
T2DM followed prospectively for 5 years described a risk
of microalbuminuria of 5% per year and identiﬁed male
sex, olderage, baseline albuminuria, HbA1c,cholesterol,and
presence of retinopathy as risk factors [48]. In addition,
glomerular hyperﬁltration (i.e., increased GFR) has been
well described in adults with T2DM, hypothesized to be
secondary to concomitant obesity and hyperglycemia. The
GFR has been shown to progressively increase and reach a
plateau once microalbuminuria develops. Once progression
to macroalbuminuria occurs, the GFR begins to decline
[49]. It is, however, not consistent in the literature that
hyperﬁltration is pathogenic, as some studies have shown
no association between hyperﬁltration and decreased GFR
[49].
The Diabetes Control and Complications Trial (DCCT)
and the United Kingdom Prospective Diabetes Study
(UKPDS) have shown that the intensity of glycemic controlInternational Journal of Pediatrics 3
signiﬁcantly impacts the development of diabetic nephropa-
thy in T1DM and adult onset T2DM [50–52]. The pediatric
literature is scant but available data suggests that glycemic
control is also an important risk factor in youth with T2DM
[30, 53]. However, the ideal target for HbA1c to minimize
the risk of nephropathy in youth with T2DM has not yet
been determined. The clinical practice guidelines currently
extrapolate from adult data to target an HbA1c ≤7% [54].
Unfortunately, this target HbA1c is diﬃcult to achieve in
youth, due in part to adolescent behavior and nonadherence
to treatment recommendations.
Y o u t hw i t ht y p e2d i a b e t e sh a v eah i g hp r e v a l e n c eo fc o -
morbidities such as obesity, hypertension, and dyslipidemia
[55, 56]. The role of these potentially modiﬁable clinical
risk factors in the development of diabetic nephropathy
has not yet been clearly deﬁned in youth onset T2DM.
Obesity is associated with glomerularhyperﬁltration and the
development of glomerulosclerosis and kidney failure [57,
58]. Renal hyperﬁltration and hypertrophy may develop in
the setting of T2DM in response to disproportionate weight
gain and declining insulin sensitivity [59]. According to
this hypothesis, adolescents with T2DM may be particularly
at risk for premature renal injury relative to adults who
experience more gradual weight gain and insulin resistance
in adulthood.
Hypertension is highly prevalent in youth with T2DM,
with a reported prevalence between 10 and 73% at diagnosis
[28, 55, 60–64]. In contrast to the T1DM and adult onset
T2DM literature [65], which consistently demonstrates hy-
pertension to be an important modiﬁable risk factor for
the development and progression of diabetic nephropathy,
the association between blood pressure control and microal-
buminuria in adolescents with T2DM is inconsistent [32,
45, 53]. A small case-control study (n = 23) revealed that
daytimesystolicbloodpressurewas∼8mmHghigheramong
youth with T2DM, relative to normoalbuminuric controls
[32]. In contrast, multivariate regression analyses from a
larger cross-sectional study and a prospective cohort study
demonstrated that systolic blood pressure is not associated
with microalbuminuria inadolescentsand youngadultswith
T2DM[30,31,53].Thesediﬀerentﬁndingsmaybeexplained
by diﬀerences in measurement techniques (casual clinic-
based measures versus 24hr blood pressure monitoring),
underpowered studies, or a lack of prospective studies with
adequate followup.
Dyslipidemia is a frequent ﬁnding in youth with T2DM
[27, 28, 31, 55, 62, 64, 66–68]. Two small studies have shown
increased LDL cholesterol and triglyceride levels in youth
with T2DM and microalbuminuria compared with those
with normal albumin excretion [30, 32], suggesting that
modiﬁcation of dyslipidemia may aﬀect risk of nephropathy.
Smoking is reported in 7–48% of youth with diabetes
[69, 70]. In T1DM, smoking has been shown to increase the
risk of microalbuminuria [71]. In addition, smoking is also
associated with a reduced GFR in adults with T1DM and
T2DM even after controlling for multiple confounders, in-
cluding microalbuminuria [72]. Strategies to help with
smoking cessation are therefore very important for these
high-risk youth.
Table 1: Deﬁnitions for albuminuria∗ [43].
Albumin:Creatinine
ratio (mg/mmol) [43]¶
24 hour collection for
albumin excretion
(mg/day)
Normal <2.0 (boys) <30
<2.8 (girls)
Microalbuminuria 2.0–20.0 (boys) 30–300
2.8–28.0 (girls)
Macroalbuminuria >20.0 (boys) >300
>28.0 (girls)
¶Must be conﬁrmed with either ﬁrst morning urine sample or overnight
urine collection.
∗Persistent albuminuria deﬁned as 2/3 positive samples over a 3–6 month
period, samples must be at least 1 month apart.
4.Pathology
Classic diabetic nephropathy is characterized by glomerular
hypertrophy, basement membrane (GBM) thickening, and
mesangial matrix expansion [73]. There is very little biopsy
data available on youthwith T2DM. In a cohort of ten Cana-
dian First Nation youth with T2DM and macroalbuminuria
who underwent renal biopsy, nine of ten biopsies exhibited
immune complex disease or glomerulosclerosis, and none
had classic diabetic nephropathy [74]. This may in part be
due to the high burden of nondiabetic primary renal disease
in Canadian First Nation populations [75–77]. Adults with
T2DM have also beenshown to havenondiabetic glomerular
disease, eithersuperimposed ondiabetic nephropathy (17%)
or more commonly without underlying diabetic disease
(28%)[78].Concomitant obesityisalsoassociated with focal
glomerulosclerosisandrenalfailure[57,58].Therefore,there
may be early changes seen in youth with T2DM related
to nondiabetic kidney disease, and obesity. The additive
eﬀects of diabetes and its associated comorbidities may alter
progression of renal dysfunction over time.
5.Screening
Canadian, American, and International guidelines [15, 54,
79]allrecommendscreeningfordiabeticnephropathyatﬁrst
presentation of diabetes. There are no validated deﬁnitions
for albuminuria in youth, therefore, the adult values are
currently utilized to stage patients (Table 1).
Albumin excretion rates in adolescents are inﬂuenced by
severalfactors includingorthostatic changes, fever,infection,
and physical activity. Therefore, it is necessary to have at
least 2 positive samples over 3 to 6 months, separated by
at least 1 month to conﬁrm the diagnosis [43]. In addition,
the diagnosis in youth should be conﬁrmed with a ﬁrst-
morning urine sample or overnight urine collection, to rule
or orthostatic proteinuria [80]. An algorithm for screening
and treatment has been proposed (Figure 1).
In addition to screening for albuminuria, screening for
concomitantcomorbidities(dyslipidemia,hypertension, and
smoking) is also recommended [54, 79, 81]. An assess-
ment of renal function should also be considered in the form4 International Journal of Pediatrics
Table 2: Recommended treatment targets that may reduce risk of nephropathy in youth with type 2 diabetes.
Clinical parameter Intervention Treatment target
Glycemic control Lifestyle/Insulin/Metformin HbA1c ≤ 7%
Prehypertension [44]( b p> 90th–95th) Lifestyle Bp < 90th percentile
Hypertension [44]( b p> 95th percentile) Lifestyle ± Ace inhibitor or Angiotensin
II Receptor Blocker Bp < 90th percentile
Dyslipidemia LDL ≥2.6mmol/L Lifestyle LDL < 2.6mmol/L
Dyslipidemia LDL >4.1mmol/L Lifestyle + Statin LDL < 2.6mmol/L
Overweight and Obesity Lifestyle BMI < 85th percentile
Smoking Cessationstrategies Nonsmoker
Annual screening with random ACR starting at
diagnosis
ACR abnormal
Yes
No
Repeat ACR 2 times in the next months at least
2 out of 3 samples abnormal
Yes-persistent albuminuria conﬁrmed
No
Conﬁrmed with at least one ﬁrst am urine ACR or
overnight urine collection for albumin excretion
Order urinalysis and routine microscopy to rule out
nondiabetic renal disease and renal ultrasound to
rule out structural renal disease
Evidence of nondiabetic renal disease (nephrotic
range proteinuria, hematuria, anatomical abnormality)
Yes
Refer to pediatric nephrology
No
Treat with ACE or ARB and
optimize HbA1c and blood
pressure
Rescreen in 1
year (annual
screening)
Pathologic albuminuria conﬁrmed
3–6
ACR = albumin to creatinine ratio
ACE = angiotensin converting enzyme inhibitor
ARB = angiotensin II receptor blocker
HbA1c = hemoglobinA1c
1 month apart (ideally 1st a.m. samples)
Figure 1: Screening algorithm for albuminuria in youth with type 2 diabetes (modiﬁed from CDA guidelines) [43].International Journal of Pediatrics 5
of an estimated glomerular ﬁltration rate [43, 82]. A uri-
nalysis and a renal ultrasound should be performed. The
presence of hematuria or red blood cell casts raises the pos-
sibility that a nondiabetic kidney disease could be present.
In those cases, a glomerulonephritis workup should be
initiated, and a renal biopsy considered. In the event of
macroalbuminuria, evidence of nondiabetic kidney disease,
or an atypical course, a referral to a pediatric nephrologist is
recommended.
6.Treatmentof NephropathyandAssociated
Comorbidities(Table 2)
First line in the prevention and treatment of nephropathy
associated with T2DM is lifestyle modiﬁcation and behavior
change, including weight reduction, low-sodium diet, and
exercise [17] in order to optimize glycemic control and
reduce comorbidities such as obesity, hypertension, and hy-
percholesterolemia. Smoking cessation strategies should be
implemented. Unfortunately, this type of therapy requires
signiﬁcant buy in from patients, families, and health care
providers. This patient populationis particularly challenging
to treat due to their adolescent age, as well as the very high
rates of lower socioeconomic status (SES). In the TODAY
study, 41.5% of participants had a household income
< $25,000[33], and inManitoba 59.1%ofyouthwith T2DM
are in the lowest SES quintile [34]. If lifestyle modiﬁcation
is not suﬃcient to reduce and maintain HbA1c to <9%
(target HbA1c is ≤7%), then pharmacologic management is
indicated, in the form of insulin and/or metformin [17, 54,
81], which is the only oral hypoglycemic agent that has been
approved(in2000)bytheUSFoodandDrugAdministration
[83, 84].
Intheabsenceofconcretebloodpressure datainchildren
with diabetes, the current guidelines recommend targeting
normal blood pressures in children with T2DM (<90th
percentile for age and height, or a maximum of <130/80),
[17,44]notonlytopotentially reducetherisk ofrenal injury,
but to decrease the risk of cardiovascular disease [17, 54, 81].
AngiotensinIIreceptorblockers(ARBs)havebeenusedmost
often in studies of adult onset T2DM and have been shown
to consistently reduce the rate of progression from microal-
buminuria to macroalbuminura [85–87]. Angiotensin-
converting enzyme (ACE) inhibitors have also been evalu-
ated and been shown to decrease the risk of microalbumin-
uria in normoalbuminuric patients with T2DM [88]. No
studies have evaluated these drugs in youth with T2DM.
There is a small number of nonrandomized studies in youth
with T1DM, all of which have shown reductions in albumin-
uria with ACE inhibitors [89–91]. Treatment with an ACE
or ARB is therefore considered ﬁrst-line therapy for both
hypertension and microalbuminuria in youth with T2DM
[17, 81]. If treatment targets are not achieved with one
medication, then it is recommended that a second agent be
added [17]. Female patients must be advised that congenital
malformations,evenintheﬁrsttrimester, havebeenreported
with ACE and ARB use [92]. Contraception counseling is
thus very important when these drugs are being used.
Treatment of hyperlipidemia is more controversial. Life-
style modiﬁcation is considered ﬁrst-line therapy, and im-
provement in glycemic control often results in improved
lipid levels.Iflifestyle fails, thenpharmacologicmanagement
with HMG CoA reductase inhibitors is recommended. The
Canadian Diabetes Association currently recommends tar-
gets used for familial hyperlipidemia for initiation of phar-
macologic agents, as studies done in this particular group
have not yet been done. A low-density lipoprotein (LDL)
threshold value >4.1mmol/L is utilized to initiate pharma-
cologic management if there is a family history of early
cardiovascular events or ≥4.9mmol/L in the absence of
cardiovascular events [54, 93]. In contrast, the International
Society for Pediatric and Adolescent Diabetes recommends a
stricter target of <2.6mmol/L, based on adult data [94].
7.Conclusions
The prevalence of type 2 diabetes in youth continues to in-
crease and is associated with microalbuminuria early in the
course of disease. The rate of progression to ESKD is in
keeping with adult onset disease. Poor metabolic control
and co-morbidities such as hypertension, dyslipidemia, and
smoking are highly prevalent and likely hasten the progres-
sion of diabetic nephropathy and chronic kidney disease.
Multifactorial-based prevention and treatment approaches
focusing on lifestyle modiﬁcation and incorporating phar-
macologicmanagementofhyperglycemia,hypertension, and
albuminuria have been proven in adult studies. Similar
strategies are also likely important to delay progression to
ESKD in youth with T2DM, however, more research is
required to better deﬁne the natural history of diabetic
nephropathy and optimal treatment targets and therapies in
this high-risk population.
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